Publications by authors named "Cristina D Kelemen"
Article Synopsis
- Venetoclax (VEN) shows promising activity against various lymphomas and leukemias, but remissions tend to be short, prompting the need for combination therapies.
- Research found that combining VEN with A1155463, a BCL-XL inhibitor, created a strong synergistic effect and could overcome resistance in certain cell lines, even those lacking BCL2L11/BIM, which is often linked to VEN resistance.
- In vivo studies confirmed the effectiveness of this combination in multiple patient-derived models, and a unique treatment schedule of 4 days on/3 days off minimized side effects, making this a potential innovative approach for treating BCL2+ hematologic malignancies.
Article Synopsis
- Bcl-2 family proteins, particularly Bax and Bak, are known for regulating apoptosis but also exhibit less understood activities unrelated to cell death.
- Research on Bax/Bak-deficient human cancer cells revealed that U87 glioblastoma cells showed enhanced respiratory function and faster proliferation, while HBL-2 B lymphoma cells experienced slight respiratory suppression.
- The study indicates that the regulation of mitochondrial transcription elongation factor TEFM in Bax/Bak-deficient cells affects mitochondrial respiratory complex subunits, influencing metabolism and cell proliferation.
The characterization of protein-protein interactions (PPIs) is of high value for understanding protein function. Two strategies are popular for identification of PPIs direct from the cellular environment: affinity capture (pulldown) isolates the protein of interest with an immobilized matrix that specifically captures the target and potential partners, whereas in BioID, genetic fusion of biotin ligase facilitates proximity biotinylation, and labeled proteins are isolated with streptavidin. Whilst both methods provide valuable insights, they can reveal distinct PPIs, but the basis for these differences is less obvious.
View Article and Find Full Text PDFArticle Synopsis
- MCL1 protein is commonly overexpressed in various cancers, including B-cell non-Hodgkin lymphomas (B-NHL), and its specific inhibitor, S63845, was studied for its effectiveness in treating these cancers.
- The research found that the expression levels of BCL2 protein significantly affect how lymphoma cells respond to S63845, with BCL2-positive cells showing resistance and BCL2-negative cells being more susceptible to treatment.
- Combining S63845 with another drug, venetoclax, proved to be particularly effective for overcoming resistance in BCL2-positive lymphoma models, highlighting the importance of both MCL1 and BCL2 levels in treatment outcomes.
Two new aromadendrin rhamnosides, cissusfoliate A () and 3--cissusfoliate A () together with seven known compounds (-) were isolated from the roots of Planch. Their structures were determined by extensive spectroscopic methods. The absolute configurations of compounds were assigned by combination of the coupling constant values of H-2 and H-3 and the comparison of their experimental ECD spectra with those reported in literature.
View Article and Find Full Text PDF